149 related articles for article (PubMed ID: 16583406)
1. Weight gain associated with the alpha2a-adrenergic receptor -1,291 C/G polymorphism and olanzapine treatment.
Park YM; Chung YC; Lee SH; Lee KJ; Kim H; Byun YC; Lim SW; Paik JW; Lee HJ
Am J Med Genet B Neuropsychiatr Genet; 2006 Jun; 141B(4):394-7. PubMed ID: 16583406
[TBL] [Abstract][Full Text] [Related]
2. Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and olanzapine-induced weight gain among Korean schizophrenic patients.
Park YM; Cho JH; Kang SG; Choi JE; Lee SH; Kim L; Lee HJ
J Clin Pharm Ther; 2008 Feb; 33(1):55-60. PubMed ID: 18211617
[TBL] [Abstract][Full Text] [Related]
3. Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study.
Ujike H; Nomura A; Morita Y; Morio A; Okahisa Y; Kotaka T; Kodama M; Ishihara T; Kuroda S
J Clin Psychiatry; 2008 Sep; 69(9):1416-22. PubMed ID: 19193342
[TBL] [Abstract][Full Text] [Related]
4. Possible association between the -2548A/G polymorphism of the leptin gene and olanzapine-induced weight gain.
Kang SG; Lee HJ; Park YM; Choi JE; Han C; Kim YK; Kim SH; Lee MS; Joe SH; Jung IK; Kim L
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):160-3. PubMed ID: 17804136
[TBL] [Abstract][Full Text] [Related]
5. Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia.
Ellingrod VL; Bishop JR; Moline J; Lin YC; Miller DD
Psychopharmacol Bull; 2007; 40(1):57-62. PubMed ID: 17285096
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoid type 1 receptor gene polymorphisms are not associated with olanzapine-induced weight gain.
Park YM; Choi JE; Kang SG; Koo SH; Kim L; Geum D; Lee HJ
Hum Psychopharmacol; 2011; 26(4-5):332-7. PubMed ID: 21695734
[TBL] [Abstract][Full Text] [Related]
7. TNF-α -308 G>A polymorphism and weight gain in patients with schizophrenia under long-term clozapine, risperidone or olanzapine treatment.
Huang HH; Wang YC; Wu CL; Hong CJ; Bai YM; Tsai SJ; Liou YJ
Neurosci Lett; 2011 Oct; 504(3):277-80. PubMed ID: 21967963
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Houston JP; Kohler J; Bishop JR; Ellingrod VL; Ostbye KM; Zhao F; Conley RR; Poole Hoffmann V; Fijal BA
J Clin Psychiatry; 2012 Aug; 73(8):1077-86. PubMed ID: 22967772
[TBL] [Abstract][Full Text] [Related]
9. Pilot study of the G-protein beta3 subunit gene (C825T) polymorphism and clinical response to olanzapine or olanzapine-related weight gain in persons with schizophrenia.
Bishop JR; Ellingrod VL; Moline J; Miller D
Med Sci Monit; 2006 Feb; 12(2):BR47-50. PubMed ID: 16449941
[TBL] [Abstract][Full Text] [Related]
10. A hypothesis-driven association study of 28 nuclear-encoded mitochondrial genes with antipsychotic-induced weight gain in schizophrenia.
Gonçalves VF; Zai CC; Tiwari AK; Brandl EJ; Derkach A; Meltzer HY; Lieberman JA; Müller DJ; Sun L; Kennedy JL
Neuropsychopharmacology; 2014 May; 39(6):1347-54. PubMed ID: 24196945
[TBL] [Abstract][Full Text] [Related]
11. Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine.
Ellingrod VL; Perry PJ; Ringold JC; Lund BC; Bever-Stille K; Fleming F; Holman TL; Miller D
Am J Med Genet B Neuropsychiatr Genet; 2005 Apr; 134B(1):76-8. PubMed ID: 15666332
[TBL] [Abstract][Full Text] [Related]
12. Association study of brain-derived neurotrophic factor gene polymorphisms and body weight change in schizophrenic patients under long-term atypical antipsychotic treatment.
Tsai A; Liou YJ; Hong CJ; Wu CL; Tsai SJ; Bai YM
Neuromolecular Med; 2011 Dec; 13(4):328-33. PubMed ID: 21956459
[TBL] [Abstract][Full Text] [Related]
13. HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis.
Ma X; Maimaitirexiati T; Zhang R; Gui X; Zhang W; Xu G; Hu G
Int J Psychiatry Clin Pract; 2014 Oct; 18(4):229-42. PubMed ID: 25152019
[TBL] [Abstract][Full Text] [Related]
14. Protein kinase cAMP-dependent regulatory type II beta (PRKAR2B) gene variants in antipsychotic-induced weight gain.
Gagliano SA; Tiwari AK; Freeman N; Lieberman JA; Meltzer HY; Kennedy JL; Knight J; Müller DJ
Hum Psychopharmacol; 2014 Jul; 29(4):330-5. PubMed ID: 24737441
[TBL] [Abstract][Full Text] [Related]
15. Association of a functional polymorphism in neuropeptide Y with antipsychotic-induced weight gain in schizophrenia patients.
Tiwari AK; Brandl EJ; Weber C; Likhodi O; Zai CC; Hahn MK; Lieberman JA; Meltzer HY; Kennedy JL; Müller DJ
J Clin Psychopharmacol; 2013 Feb; 33(1):11-7. PubMed ID: 23277265
[TBL] [Abstract][Full Text] [Related]
16. G-protein beta3 Subunit Gene 825C/T Polymorphism Is Not Associated with Olanzapine-Induced Weight Gain in Korean Schizophrenic Patients.
Park YM; Chung YC; Lee SH; Lee KJ; Kim H; Choi JE; Kang SG; Lee MS; Kim L; Lee HJ
Psychiatry Investig; 2009 Mar; 6(1):39-43. PubMed ID: 20046372
[TBL] [Abstract][Full Text] [Related]
17. Possible association of the pro-melanin-concentrating hormone gene with a greater body mass index as a side effect of the antipsychotic olanzapine.
Chagnon YC; Bureau A; Gendron D; Bouchard RH; Mérette C; Roy MA; Maziade M
Am J Med Genet B Neuropsychiatr Genet; 2007 Dec; 144B(8):1063-9. PubMed ID: 17541984
[TBL] [Abstract][Full Text] [Related]
18. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
Kinon BJ; Basson BR; Gilmore JA; Tollefson GD
J Clin Psychiatry; 2001 Feb; 62(2):92-100. PubMed ID: 11247108
[TBL] [Abstract][Full Text] [Related]
19. Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism.
Miller DD; Ellingrod VL; Holman TL; Buckley PF; Arndt S
Am J Med Genet B Neuropsychiatr Genet; 2005 Feb; 133B(1):97-100. PubMed ID: 15635667
[TBL] [Abstract][Full Text] [Related]
20. The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients.
Kuzman MR; Medved V; Bozina N; Hotujac L; Sain I; Bilusic H
Psychiatry Res; 2008 Sep; 160(3):308-15. PubMed ID: 18718676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
